Eilean Therapeutics is a small molecule oncology drug discovery company that develops pan-variant therapies for hematologic malignancies targeting major drivers of cancer resistance.

Eilean Therapeutics

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Tak Mak

Lewis Cantley

Craig Thompson

Shin-San Michael Su

Agios Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Metric
Company Name	Eilean Therapeutics	Agios Pharmaceuticals, Inc.	Alnylam Pharmaceuticals, Inc.	Arvinas, Inc.
Symbol		AGIO	ALNY	ARVN
MSH ID	COM:EILEANTHER	COM:AGIOS	COM:ALNYLAM	COM:ARVINAS
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count		383	2.10K	445
Website	eileanther.com	agios.com	alnylam.com	arvinas.com
LinkedIn				arvinas
Founders

Metric
Market Cap	2.47B	32.60B	1.80B
Enterprise Value
Monthly Web Traffic		55.97K
Web Traffic Growth		0.89
Valuation
Raised Capital		900M

Metric
Revenue	26.82M	1.83B	78.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit	17.32M	1.52B	71.80M
EBITDA	-384.86M	-228.12M	-394.80M
Operating Income	-391.49M	-282.18M	-401.50M
Net Income	-352.09M	-440.24M	-367.30M
EPS	-6.33	-3.52	-6.62
Diluted EPS	-6.33	-3.52	-6.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.84	0.87	0.95
Operating Profit Margin	-12.94	0.04	-3.98
EBITDA Margin	-14.35	-0.12	-5.03
Net Profit Margin	-11.66	-0.03	-3.47
Return on Equity	-0.37	1.67	-0.56
Return on Assets	-0.37	-0.02	-0.25
Return on Capital Employed	-0.45	0.03	-0.38

COM:EILEANTHER

Eilean Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-23.82	-42.10	-8.65
P/B Ratio	1.37	-129.43	5.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	96.00	16.84	37.00
EV Multiple	-4.30	326.32	-4.38

Metric
Days Sales Outstanding	40.78	68.92	47.11
Days Payables Outstanding	1.64K	97.72
Days Inventory Outstanding	1.63K	128.53
Operating Cycle	1.66K	187.09	87.03
Cash Conversion Cycle	830.26	104.98	87.03
Asset Turnover	0.04	0.58	0.07

Metric
Operating Cash Flow	-296.06M	104.16M	-347.80M
Free Cash Flow	-297.06M	41.95M	-350.70M
Cash Flow to Debt	-4.11	0.15	-102.43
Operating Cash Flow/Sales	-9.79	0.16	-2.31
Free Cash Flow Yield	-0.23	-0.00	-0.13

Metric
Cash & Equivalents	88.20M	812.69M	317.20M
Accounts Receivable	-604K	-87.94M	800K
Inventory	19.08M	89.15M
Goodwill
Debt to Capitalization	0.09	1.20	0.00
Debt to Assets	0.07	0.34	0.00
Current Ratio	13.73	3.14	3.26
Quick Ratio	12.39	3.07	4.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	2.21	0.13	0.47
R&D to Revenue	13.47	0.58	2.40
SG&A to Revenue		0.35	0.55